Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzyme, according to a Tuesday filing with the Australian bourse.
The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis. Its primary endpoint is efficacy, with safety as part of the secondary endpoints, the filing said.
Company shares rose 4% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。